# Supplementary Figure 1

Examples of immunogenic SARS-CoV-2-derived HLA class I T-cell epitopes as evaluated in IFNγ ELISPOT assays. IFNγ ELISPOT assays were performed after 12-day stimulation with the respective SARS-CoV-2-derived HLA class I-binding peptides using PBMCs from convalescent SARS-CoV-2-infected HLA-matched donors. Peptides were analyzed in duplicates. Bars indicate mean spot counts of duplicates normalized to 5 x 10^5 cells with standard deviation. HLA-matched human self-peptides or HIV-derived peptides served as negative control. Neg., negative control.

Supplemental Figure 2

Examples of immunogenic SARS-CoV-2-derived HLA-DR T-cell epitopes as evaluated in IFNγ ELISPOT assays. IFNγ ELISPOT assays were performed after 12-day stimulation with the respective SARS-CoV-2-derived HLA-DR-binding peptides using PBMCs from reconvalescent SARS-CoV-2-infected donors. Peptides were analyzed in duplicates expect for SARS019. Bars indicate mean spot counts of duplicates normalized to 5×10^5 cells with standard deviation. The Filamin-A-derived peptide ETVITVDTKAAGKGK served as negative control. Neg., negative control.

Supplementary Figure 3

Intensity of T-cell responses against SARS-CoV-2 HLA class I- and HLA-DR-binding peptides as evaluated in IFNγ ELISPOT assays. IFNγ ELISPOT assays were performed after 12-day stimulation with the respective SARS-CoV-2 peptides using PBMCs from convalescent SARS-CoV-2-infected donors. Dots represent individual donors. Bars represent mean values with standard deviation.